Therapeutic drug monitoring of antiarrhythmic drugs

被引:0
|
作者
Jürgens, G
Graudal, NA
Kampmann, JP
机构
[1] Copenhagen Univ Hosp, Dept Clin Pharmacol, DK-2100 Copenhagen O, Denmark
[2] Univ Copenhagen, Herlev Hosp, Dept Internal Med & Rheumatol Q, DK-2730 Herlev, Denmark
[3] Med Agcy, Inst Rat Pharmacotherapy, Copenhagen, Denmark
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most antiarrhythmic drugs fulfil the formal requirements for rational use of therapeutic drug monitoring, as they show highly variable plasma concentration profiles at a given dose and a direct concentration-effect relationship. Therapeutic ranges for antiarrhythmic drugs are, however, often very poorly defined. Effective drug concentrations are based on small studies or studies not designed to establish a therapeutic range, with varying dosage regimens and unstandardised sampling procedures. There are large numbers of nonresponders and considerable overlap between therapeutic and toxic concentrations. Furthermore, no study has ever shown that therapeutic drug monitoring makes a significant difference in clinical outcome. Therapeutic concentration ranges for antiarrhythmic drugs as they exist today can give an overall impression about the drug concentrations required in the majority of patients. They may also be helpful for dosage adjustment in patients with renal or hepatic failure or in patients with possible toxicological or compliance problems. Their use in optimising individual antiarrhythmic therapy, however, is very limited.
引用
收藏
页码:647 / 663
页数:17
相关论文
共 50 条
  • [1] Therapeutic drug monitoring: antiarrhythmic drugs
    Campbell, TJ
    Williams, KM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 : 21S - 34S
  • [2] Therapeutic drug monitoring: antiarrhythmic drugs
    Campbell, TJ
    Williams, KM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (04) : 307 - 319
  • [3] Therapeutic Drug Monitoring of Antiarrhythmic Drugs
    Gesche Jürgens
    Niels A. Graudal
    Jens P. Kampmann
    Clinical Pharmacokinetics, 2003, 42 (7) : 647 - 664
  • [4] THERAPEUTIC DRUG-MONITORING OF ANTIARRHYTHMIC DRUGS RATIONALE AND CURRENT STATUS
    LATINI, R
    MAGGIONI, AP
    CAVALLI, A
    CLINICAL PHARMACOKINETICS, 1990, 18 (02) : 91 - 103
  • [5] Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring
    Takada, M
    Goto, T
    Kotake, T
    Saito, M
    Kawato, N
    Nakai, M
    Gunji, T
    Shibakawa, M
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2005, 30 (01) : 5 - 12
  • [7] THERAPEUTIC DRUG-MONITORING OF ANTIARRHYTHMIC AGENTS
    BROWN, JE
    SHAND, DG
    CLINICAL PHARMACOKINETICS, 1982, 7 (02) : 125 - 148
  • [8] Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug
    Doki, Kosuke
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2018, 138 (09): : 1145 - 1150
  • [9] Therapeutic Drug Monitoring of Antidementia Drugs
    Koeber, Ralf
    Kluenemann, Hans Hermann
    Waimer, Reinhold
    Koestlbacher, Anton
    Doerfelt, Arnett
    Outlaw, Eva
    Melchner, Doris
    Haen, Ekkehard
    BIOLOGICAL PSYCHIATRY, 2011, 69 (09) : 91S - 91S
  • [10] Therapeutic drug monitoring - antiepileptic drugs
    Eadie, MJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 : 11S - 20S